Progestogen safety and tolerance in hormonal replacement therapy

References

• Wentz WB. Progestin therapy in endometrial hyperplasia. Gynecol Oncol. 1974;2:362–367.
   PubMedGoogle Scholar
• Whitehead MI, Fraser D. Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol. 1987;156:1313–1322.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995 Nov–Dec;38(3):199–210.
   PubMed Web of Science ®Google Scholar
• Rossouw J, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators risks and benefits of estrogen plus progestogen in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013 Oct 2;310(13):1353–1368. doi:10.1001/JAMA.2013.278040.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol. 2015 Jun;1(3):296–305.
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society. Menopause. 2003;10:113–132.
   PubMed Web of Science ®Google Scholar
• Hapgood JP, Africander D, Louw R, et al. Potency of progestogens used in hormonal therapy: toward understanding differential actions. J Steroid Biochem Mol Biol. 2014 Jul;142:39–47.
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013 Apr;34(2):171–208.
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause. 2005;12:232–237.
   PubMed Web of Science ®Google Scholar
• Nillius SJ, Johansson EDB. Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol. 1971;110:470–477.
   PubMed Web of Science ®Google Scholar
• Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485–490.
   PubMed Web of Science ®Google Scholar
• Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen stimulated endometrium. Fertil Steril. 2003;79:221–222.
   PubMed Web of Science ®Google Scholar
• Rarick L. United States regulatory considerations for intrauterine progestogens for hormone replacement therapy. Contraception. 2007;75:S140–S143.
   Google Scholar
• Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443–451.
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestogen Interventions (PEPI) Trial. JAMA. 1996;275:370–375.
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Million Women Study Collaborators. Lancet. 2005;365:1543–1551.
   PubMed Web of Science ®Google Scholar
• Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. ‎Int J Cancer. 2010 Jul 15;127(2):442–451.
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2010;172:1394–1403.
   PubMed Web of Science ®Google Scholar
• Karageorgi S, Hankinson SE, Kraft P, et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976–2004. Int J Cancer. 2010;126:208–216.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, De Ziegler D, Galantino P, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol. 2002;187:556–560.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, De Ziegler D, Alfonso R, et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril. 2005;83:1859–1863.
   PubMed Web of Science ®Google Scholar
• Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005;20:2653–2660.
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril. 1999;72:161–163.
   PubMed Web of Science ®Google Scholar
• Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril. 2001;76:969–973.
   PubMed Web of Science ®Google Scholar
• Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994;83:686.
   PubMed Web of Science ®Google Scholar
• Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 1982;27:539.
   PubMed Web of Science ®Google Scholar
• Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol. 1995;86:306.
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Interventions Trial. Obstet Gynecol. 1998;92:982–988.
   PubMed Web of Science ®Google Scholar
• Goletiani NV, Keith DR, Gorsky SJ. Special section: progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007;15(5):427–444.
   PubMed Web of Science ®Google Scholar
• Apgar BS, Greenberg G. Using progestogens in clinical practice. Am Fam Physician. 2000 Oct 15;62(8):1839–1846, 1849–1850.
   PubMed Web of Science ®Google Scholar
• Heinrich AB, Wolf OT. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. Neuropsychobiology. 2005;52:17–23.
   PubMed Web of Science ®Google Scholar
• Kirkham C, Hahn PM, Van Vugt DA, et al. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy. Obstet Gynecol. 1991;78:93–97.
   PubMed Web of Science ®Google Scholar
• Siddle NC, Fraser D, Whitehead MI, et al. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol. 1990;97:1101–1107.
   PubMedGoogle Scholar
• Cagnacci A, Arangino S, Baldassari F, et al. A comparison of the central effects of different progestins used in hormone replacement therapy. Maturitas. 2004;48:456–462.
   PubMed Web of Science ®Google Scholar
• Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 2002;9:253–263.
   PubMed Web of Science ®Google Scholar
• Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004;7(2):189–196.
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12(6):716–727.
   PubMed Web of Science ®Google Scholar
• Lee BS, Kang BM, Yoon BK, et al. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007;57(4):361–369.
   PubMed Web of Science ®Google Scholar
• Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007;10(Suppl 1):3–10.
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck AO. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? J Steroid Biochem Mol Biol. 2008;109:11–15.
   PubMed Web of Science ®Google Scholar
• Krämer EA, Seeger H, Krämer B, et al. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77–83.
   PubMed Web of Science ®Google Scholar
• De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013 Jun;16(3):316–337.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003 Jun 25;289(24):3243–3253.
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006 Apr 12;295(14):1647–1657.
   PubMed Web of Science ®Google Scholar
• Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause. 2005;12(6):668–678.
   PubMed Web of Science ®Google Scholar
• Panoulis C, Lambrinoudaki I, Vourtsi A, et al. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density. Climacteric. 2009 Jun;12(3):240–247. doi:10.1080/13697130802684601.
   PubMed Web of Science ®Google Scholar
• Stuedal A, Ma H, Bjørndal H, et al. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric. 2009 Jun;12(3):248–258.
   PubMed Web of Science ®Google Scholar
• Burger HG. WHI risks: any relevance to menopause management? Maturitas. 2007;57:6–10.
   PubMed Web of Science ®Google Scholar
• Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001 Jul 24;104(4):499–503.
   PubMed Web of Science ®Google Scholar
• Lundström E, Wilczek B, Von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric. 2001 Mar;4(1):42–48.
   PubMedGoogle Scholar
• Gramling R, Eaton CB, Rothman KJ, et al. Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology. 2009 Sep;20(5):752–756. doi:10.1097/EDE.0b013e3181a71279.
   PubMed Web of Science ®Google Scholar
• Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997 Dec 1;127(11):973–980.
   PubMed Web of Science ®Google Scholar
• Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998;90:814–823.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005;84(2):485–491.
   Web of Science ®Google Scholar
• Formoso G, Perrone E, Maltoni S, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012 Feb 15;2:CD008536.
   Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008 Aug 14;359(7):697–708. doi:10.1056/NEJMoa0800743.
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1–9.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008 Jan;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009 Jan;113(1):65–73. doi:10.1097/AOG.0b013e31818e8cd6.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613.
   PubMed Web of Science ®Google Scholar
• Haskell WD. Noncardiovascular disease outcomes during 6,8 years of hormone therapy heart estrogen/progestogen replacement study follow-up (HERS II). JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Alving B. NIH asks participants in Women’s Health Initiative estrogen-alone study to stop study pills, begin follow-up phase. South Med J. 2004 Apr;97(4):425–426.
   PubMed Web of Science ®Google Scholar
• Skouby SO. Consequences for HRT following the HERS and WHI reports: the primun non nocere is important, but translation into quo vadis is even more essential. Acta Obstet Gynecol Scand. 2002;8:1793–1798.
   Google Scholar
• Howard BV, Rossouw JE. Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative. Curr Opin Lipidol. 2013 Dec;24(6):493–499.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9;345:e6409.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestogen and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534.
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med. 2006;166:357–365.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy early postmenopausal women. Arch Intern Med. 2004;164:482–484.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014 Aug 19;161(4):249–260.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016 Mar 31;374(13):1221–1231.
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519. doi:10.1136/bmj.c2519.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007 Feb 20;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009 Oct;12(5):445–453.
   PubMed Web of Science ®Google Scholar
• Palacios S, Mejía Ríos A. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women. Drugs Today (Barc). 2015 Feb;51(2):107–116.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025–1038.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116–1124.
   PubMed Web of Science ®Google Scholar
• Komm B. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15:984–992.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Chines AA, Racketa J, et al. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause. 2010;17:1237–1238.
   Web of Science ®Google Scholar
• Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause. 2013;20:138–145.
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17:281–289.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76(1):13–24.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Taylor H, Pan K, et al. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause. 2010;17(6):1221–1222.
   Web of Science ®Google Scholar